Existing investor Syngenta Ventures was among the participants as the agricultural bioprocessing platform developer raised capital that will support commercialisation.

US-based bioprocessing technology developer GreenLight Biosciences closed an $18m series D round yesterday featuring Syngenta Ventures, the strategic investment arm of agribusiness Syngenta. Private equity firm Fall Line Capital led the round, which was also backed by S2G Ventures, Lewis and Clark Ventures, Macro Capital Investments and existing investors that included Kodiak Venture Partners and…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.